On September 4-5, 2014, industry leaders will convene in Boston to discuss promoting patient empowerment in clinical research, leveraging innovation, and collaboration. The conference will open with a keynote by Ken Getz, Director of Sponsored Research at Tufts CSDD, and is co-chaired by Christine Pierre, President of the Society for Clinical Research Sites (SCRS) and Andreas Koester, Vice President of …
A PALB2 Mutation Associated with High Risk of Breast Cancer
From: medscape.com Abstract Introduction: As a group, women who carry germline mutations in partner and localizer of breast cancer 2 susceptibility protein (PALB2) are at increased risk of breast cancer. Little is known about by how much or whether risk differs by mutation or family history, owing to the paucity of studies of cases unselected for family history. Methods: We …
NHS Delays Leave Unlucky British Residents To Die Of Cancer Earlier
By: Sarah Hurtubise From: dailycaller.com Delays in some parts of Britain’s single-payer health care system are leaving certain residents to die more quickly of cancer, according to an analysis from a British cancer charity. A Macmillan study of data from the British government found that cancer survival rates across the National Health Services local hospital groups, called clinical commissioning groups …
Prostate cancer drug abiraterone ‘too expensive’ to use on terminally-ill patients
By: Charlie Cooper From: independent.co.uk Thousands of terminally ill prostate cancer patients in England will be denied early access to a drug which can both extend life and reduce pain, after the medicines watchdog ruled it would be too expensive for the NHS – the second such decision in as many weeks. Abiraterone, a drug for advanced prostate cancer which …
Insurance status may affect cancer outcome
By Randy Dotinga From: usnews.com A new U.S. study finds that cancer patients who don’t have insurance — or who get it through the federal health insurance program for the poor (Medicaid) — are at much higher risk of poor medical outcomes than other people. They’re more likely to have advanced cancer when they’re diagnosed, less likely to be treated …
Salt injection ‘kills cancer cells’
By Press Association From: dailymail.co.uk Scientists have created a technique which can cause cancer cells to self-destruct by injecting them with salt. Researchers from the University of Southampton are part of an international team that has helped to create a molecule that can cause cancer cells to die by carrying sodium and chloride ions into the cells. Synthetic ion transporters …
Chemical used in Colgate Total toothpaste is linked to cancer
By Lydia Warren From: dailymail.co.uk A chemical that has been linked to cancer cell growth is being used by millions of Americans in toothpaste every day, it has emerged. The company behind Colgate Total insists that triclosan, which it uses to stave off gum disease, is safe to use because the toothpaste was approved in 1997 by the Food and …
La, Miss hospitals form cancer drug test network
By: JANET McCONNAUGHEY From: theadvocate.com Cancer patients in Louisiana and south Mississippi will find it easier to join tests of treatments and promising new drugs under a network organized by the LSU cancer centers in New Orleans and Shreveport. Officials say including local hospitals and clinics will reduce the need for patients to travel, likely increasing the number who can …
New cancer classification system shows promise as lifesaver
By: Victoria Colliver From: sfgate.com Classifying cancer tumors by their molecular structure rather than the tissue or organ where they were found, such as the breast or bladder, may lead to more accurate diagnoses and potentially better treatments and outcomes for patients, a new study finds. In the largest undertaking to analyze and compare different cancer types based on genomic sequencing, …
Cynvenio launches breast cancer Therapy Finder powered by CollabRx
Cynvenio, a cancer diagnostics company focused on transforming cancer treatment and management through the genomic analysis of tumor cells in the bloodstream, announced Therapy Finder™, a web-based cancer decision support application powered by CollabRx, Inc. [NASDAQ: CLRX]. Available as a reporting option with Cynvenio’s ClearID™ genomic test, Therapy Finder will provide breast cancer patients and their physicians with a dynamic …